ABUS
Arbutus Biopharma·NASDAQ
--
--(--)
--
--(--)
6.22 / 10
Outperform
Sentiment is Outperform (6.22) with a fund‑flow score of 7.83 (good). Inflows are positive across all size segments. Analyst consensus is a single Strong Buy, indicating bullish expectations despite limited coverage.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Keay NakaeStrong Buy
Date2025-11-14
InstitutionChardan Capital
Times predicted3
Historical Win Rate33.3%
What is the market sentiment for ABUS?
- ABUS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.22/10 (Outperform).
